Role of Biomarkers in Cancer Drug Development: A Mini Review

Download Article

DOI: 10.21522./TIJBMS.2016.03.02.Art001

Authors : Sayanth Raj, Niharika Anand, Jessica Dasari, Imran Shareef Syed, Rozmina Banu


Biomarkers, or biological markers, are defined in various ways. Some define it as ‘a biologic feature that can be used to measure the presence or progress of disease or the effects of treatment. One goal of biomarker usage in clinical research is to expedite the drug development process to produce drug therapies as efficiently as possible, while maintaining the safety profile. Biomarkers have been used for decades, from monitoring blood pressure to lipid levels. Tumor biomarkers represent an effective tool for tumor diagnosis, treatment, prognosis, and therapeutic monitoring. Ideally, the use of biomarkers in early trials would help predict the likelihood of success or failure of a drug in efficacy trials. Biomarkers can predict drug efficacy more quickly than conventional clinical end points; they hold the potential to substantially accelerate product development in certain disease. This review is mainly focused on the role biomarkers in cancer drug development process and the literature was collected from articles published in PUBMED, Medline, and the Cochrane Database of Systemic Reviews.

Keywords: Biomarkers; Clinical trials; Drug Development; Cancer.


[1].     Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nature reviews 2005, 5(1):65-72.

[2].      Bernardo HL, Goulart, Clark JW, Pien HH, et al. Trends in the Use and Role of Biomarkers in Phase I Oncology Trials. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6719-26.

[3].     Yeh CN, Chen TW, Wu TJ, et al. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. World Journal of Gastroenterology. 2006; 12(23):3760-5.

[4]. Guo J, Li Y, Lam CWK. ZH-1 enhances the anticancer activity of gemcitabine via deoxyribonucleotide synthesis and apoptotic pathway against A549 cells. Food Chem Toxicol. 2018; 15(18) 30221-7.

[5].  Liu Y, Lu S, Zhao L, Dong X. Effects of glaucocalyxin an on human liver cancer cells as revealed by GC/MS- and LC/MS-based metabolic profiling. Anal Bioanal Chem. 2018; 410(14): 3325-3335.

[6]. Suraweera A, O'Byrne KJ, Richard DJ. Combination Therapy with Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front Oncol. 2018 Mar 29; 8:92.

[7]. Jain KK. Proteomics-based anticancer drug discovery and development. Technol Cancer Res Treat. 2002 Aug; 1(4):231-6.

[8]. Wu ZZ, Ding GF, Huang FF, et al. Anticancer Activity of Anthopleuraanjunae Oligopeptides in Prostate Cancer DU-145 Cells. Mar Drugs. 2018 Apr 12; 16(4): 125.

[9]. Zhang WY, Yi QY, Wang YJ, et al. Photo induced anticancer activity studies of iridium (III) complexes targeting mitochondria and tubules. Eur J Med Chem. 2018 Apr 7; 151:568-584.

[10]. Jochems A, Leeneman B, Franken MG, et al. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anticancer Drugs 2018; 29(6):572-578.

[11]. Loong MT. Emerging Trends in Oncology: Greater Role for Radiology. Journal of Medical Diagnostic Methods.2012; 10(4172):2168-9784.

[12]. Robert S. Negm, Mukesh Verma, Sudhir Srivastava. The promise of biomarkers in cancer screening and detection. TRENDS in Molecular Medicine 2002; 8 (6); 221- 256.

[13]. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007; 18:175–184.

[14]. Xi Chen, Yi Ba, Chen-Yu Zhang “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases” Cell Res. 2008 Oct; 18(10):997-1006.

[15]. Moertel C. G. Chemotherapy for colorectal cancer. N. Engl. J. Med., 1994; 330:1136-1142.

[16]. Qazi F., McGuire W. P. The treatment of epithelial ovarian cancer. CA Cancer J. Clin., 1995; 45:88-101.

[17]. Satoshi Nishizuka, Sing-Tsung Chen, Fuad G. Gwadry, Jes Alexander, Sylvia M. Major. Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling. Molecular Biology, Pathobiology, and Genetics, 2003; 63 (1): 5243–5250.

[18]. Jakobsen NA, Hamdy FC, Bryant RJ. Novel biomarkers for the detection of prostate cancer. J Clin Urol. 2016; 9(2 Suppl):3-10.

[19]. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2011;5(3):492-497.

[20]. Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNAs for detecting breast cancer in the early stage. Cancer Sci. 2016; 107(3):326-34.

[21]. Xuemei Zhao, Vijay Modur, Leonidas N. Carayannopoulos, Omar F. Laterza Clinical Chemistry Nov 2015, 61 (11) 1343-1353;

[22]. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7:70. Published 2014 Oct 3. doi:10.1186/s13045-014-0070-8.